Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions
Executive Summary
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).
You may also be interested in...
‘I’m Still Here’: Woodcock’s Swan Song At US FDA Looking Like A Longer-Term Job
Janet Woodcock’s imminent departure from FDA has been predicted often during her tenure. Her latest project may keep her there longer than even she thought possible.
‘I’m Still Here’: Janet Woodcock’s Swan Song At US FDA Looking Like A Longer-Term Job
Janet Woodcock’s imminent departure from the agency has been predicted often during her tenure. Her latest project may keep her there longer than even she thought possible.
As US FDA’s Principal Deputy Commissioner, Woodcock Focusing On Food Issues
Commissioner Robert Califf wants Janet Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.